A field notebook on the zinc-bound thymic factor
Thymulin is a zinc-dependent thymic nonapeptide that drives T-cell differentiation across the research literature.
A careful reading of four decades of studies on the metallopeptide that switches on only when one zinc ion binds it — what each paper actually measured, and where the record stops.
The short version
Thymulin is a small hormone made by the thymus, the immune-training gland behind the breastbone. It is a nonapeptide — a chain of nine amino-acid building blocks — and it has one defining quirk: it only works when a single zinc atom is attached to it. Strip the zinc away and the peptide goes dead; add the zinc back and it switches on again. In laboratory and animal studies, the active zinc-bound form helps T cells (the immune system's trained defender cells) mature, and it quiets inflammation. Thymulin is a research peptide, not an approved medicine, and most of what we know comes from cells and animals.
What is thymulin?
Thymulin is a zinc-dependent nonapeptide hormone produced exclusively by thymic epithelial cells (the gland's lining cells that build the peptide). Its sequence is pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, its molecular weight is 858.86 Da, and it carries the CAS number 63958-90-7 [1]. Bach and Dardenne characterized it as a zinc-dependent hormone that promotes T-lymphocyte maturation and tunes T-cell subset functions [2].
The single fact that organizes everything else is zinc. Thymulin is biologically active only when bound to zinc(II) in a 1:1 molar ratio; the zinc-free apopeptide is inert [3]. Dardenne and colleagues showed this directly — treating the serum thymic factor with the chelator Chelex 100 abolished its activity in the rosette assay (a classical immune bioassay), and zinc salts restored it, with one metal ion per peptide giving optimal activation [1]. They proposed the name thymulin for that zinc-bound active form. It circulates from birth, peaks in childhood, and declines with age and with zinc-dependent activation running short [3].
Thymulin Peptide: A Zinc-Dependent Thymic Nonapeptide
The thymulin peptide is the linear nonapeptide pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (molecular formula C33H54N12O15), and its biological activity requires one bound zinc(II) ion per molecule [3]. Zinc binding is not incidental decoration — it gives the peptide a specific three-dimensional conformation, one that nuclear magnetic resonance can resolve in the zinc-bound form but not the apopeptide [3].
The practical consequence is that serum thymulin activity behaves as a sensitive readout of zinc status. In animals and in humans, thymulin activity falls when zinc is short and is corrected when zinc is restored [3]. That coupling is the through-line of the thymulin research findings: the peptide is the message, and zinc is what lets the message be read.
Thymulin and serum thymic factor (FTS)
Thymulin and serum thymic factor are the same molecule in two states. Serum thymic factor — FTS, from the French facteur thymique serique — is the original name for the peptide, isolated from serum before its zinc dependence was understood [1]. The zinc-free form is inactive; binding one zinc ion converts FTS into active thymulin, sometimes written FTS-Zn or Zn-thymulin [1].
The rename in 1982 was not cosmetic. It marked the discovery that there were two forms of FTS — a zinc-free, biologically inactive one and a zinc-bound, biologically active one — and that the active form deserved its own name [1]. Read "FTS," "FTS-Zn," and "thymulin" in the older literature as the same nine-residue chain at different points on its zinc switch.
What the literature establishes — and where it stops
A few findings are genuinely well-grounded. Zinc activation: chelating the metal abolishes activity and equimolar zinc restores it [1]. T-cell differentiation: synthetic FTS induced T-cell surface markers on human bone-marrow precursor cells in culture [4]. The human zinc-thymulin link: in mildly zinc-deficient adults, serum thymulin activity was depressed despite normal plasma zinc and was corrected by zinc repletion [5]. These are research findings in their study models, not approved human uses.
The honest gaps matter just as much. Thymulin is not FDA-approved for any indication and is handled as a research chemical for laboratory use only [6]. Most evidence is preclinical. Human data are sparse and dated, and several human studies used a synthetic analog (nonathymulin) rather than native thymulin [6]. Pharmacokinetics, including human half-life, are not well characterized in the public literature [7]. And consumer sources frequently confuse thymulin with other thymic peptides — a confusion worth clearing up before anything else.
How is thymulin different from thymosin alpha-1?
Thymulin is a distinct, zinc-dependent thymic nonapeptide. It is not thymosin alpha-1, which is a different thymic peptide with a different sequence and no zinc requirement; it is not thymosin beta-4; and it is not thymopentin [3]. These are chemically and pharmacologically separate molecules, and thymulin's research record should never be read through another peptide's data. The disambiguation is covered in full on the thymulin research findings page.
Is thymulin the same as thymalin?
No. Thymalin is a bovine thymic polypeptide complex — a mixture extracted from calf thymus — and it is distinct from thymulin, which is a single, defined zinc-dependent nonapeptide [3]. Consumer sources sometimes blur the two because the names rhyme and both trace to the thymus, but they are different preparations: one a characterized nine-residue peptide, the other a multi-component extract.
What is thymulin peptide?
Thymulin peptide is the linear nonapeptide pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, molecular formula C33H54N12O15, whose biological activity requires one bound zinc(II) ion per molecule [3]. It is produced solely by thymic epithelial cells [8], and its 858.86 Da chain is small even by peptide standards — nine residues, one zinc switch.